MAIA Biotechnology Inc. (MAIA) - Total Assets
Based on the latest financial reports, MAIA Biotechnology Inc. (MAIA) holds total assets worth $35.32 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
MAIA Biotechnology Inc. - Total Assets Trend (2019–2025)
This chart illustrates how MAIA Biotechnology Inc.'s total assets have evolved over time, based on quarterly financial data. Also see MAIA Biotechnology Inc. market capitalisation for the company's overall valuation and market capitalisation.
MAIA Biotechnology Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
MAIA Biotechnology Inc.'s total assets of $35.32 Million consist of 100.0% current assets and 0.0% non-current assets. Review MAIA Biotechnology Inc. total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 89215.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how MAIA Biotechnology Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See MAIA Biotechnology Inc. (MAIA) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MAIA Biotechnology Inc.'s current assets represent 100.0% of total assets in 2025, a decrease from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 89215.2% of total assets in 2025, up from 98.6% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
MAIA Biotechnology Inc. Competitors by Total Assets
Key competitors of MAIA Biotechnology Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
MAIA Biotechnology Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.59 | 2.35 | 0.44 |
| Quick Ratio | 5.59 | 2.35 | 0.44 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $28.99 Million | $6.80 Million | $-947.24K |
MAIA Biotechnology Inc. - Advanced Valuation Insights
This section examines the relationship between MAIA Biotechnology Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 33.71 |
| Latest Market Cap to Assets Ratio | 8.00 |
| Asset Growth Rate (YoY) | -4.4% |
| Total Assets | $9.70 Million |
| Market Capitalization | $77.66 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values MAIA Biotechnology Inc.'s assets at a significant premium (8.00x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: MAIA Biotechnology Inc.'s assets decreased by 4.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for MAIA Biotechnology Inc. (2019–2025)
The table below shows the annual total assets of MAIA Biotechnology Inc. from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $9.70 Million | -4.44% |
| 2024-12-31 | $10.16 Million | +34.21% |
| 2023-12-31 | $7.57 Million | -37.06% |
| 2022-12-31 | $12.02 Million | +6.13% |
| 2021-12-31 | $11.33 Million | +1417.36% |
| 2020-12-31 | $746.50K | -56.96% |
| 2019-12-31 | $1.73 Million | -- |
About MAIA Biotechnology Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illin… Read more